

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3228690

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
H. William Bosch	07/31/2013
RECEIVING PARTY DATA	
Name:	ICEUTICA PTY LTD.
Street Address:	C/O ICEUTICA, INC.
Internal Address:	ONE KEW PLACE, 150 ROUSE BOULEVARD NAVY YARD CORPORATE CENTER
City:	PHILADELPHIA
State/Country:	PENNSYLVANIA
Postal Code:	19112
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14621863
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 542-5070
Email:	apsi@fr.com
Correspondent Name:	ANITA L. MEIKLEJOHN
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	31215-0011005
NAME OF SUBMITTER:	MARY FLORCZAK
SIGNATURE:	/Mary Florczak/
DATE SIGNED:	02/17/2015
Total Attachments: 9	
source=BOSCHAssignment#page1.tif	
source=BOSCHAssignment#page2.tif	
source=BOSCHAssignment#page3.tif	

source=BOSCHAssignment#page4.tif
source=BOSCHAssignment#page5.tif
source=BOSCHAssignment#page6.tif
source=BOSCHAssignment#page7.tif
source=BOSCHAssignment#page8.tif
source=BOSCHAssignment#page9.tif

Deed of Acknowledge & Assignment of Intellectual Property Rights

H. William Bosch

and

iCeutica, Inc.

and

iCeutica Pty Ltd
ACN 113 244 152

Middletons
Melbourne office
Ref: NSIV.PTH.10028271

©Middletons 2010. All rights reserved.

PATENT
REEL: 034971 FRAME: 0246

Deed of Acknowledgment and Assignment of Intellectual Property Rights

Effective Date April 23, 2009

By

H. William Bosch of 237 Rodney Circle, Bryn Mawr, Pennsylvania 19010, United States of America

(the Assignor)

In favour of

iCeutica Pty Ltd ACN 113 244 152 of 52 Fairfield Street, Mt Hawthorn, Western Australia 6016
(Assignee)

Background

- A. The Assignor did, in the ordinary course of his respective employment with iCeutica, Inc., conceive and/or develop the inventions listed in Schedule 1 (each an **Invention**) which are disclosed and/or claimed in the respective corresponding patent applications also listed or described in schedule 1 (**Patent Applications**).
- B. The Assignor conceived and worked on the Inventions pursuant to the employment agreements between inventor and iCeutica, Inc., being the agreement dated 20 August 2007. Inventor and iCeutica, Inc. agreed that the intellectual property developed by the parties pursuant to those agreements would be owned by iCeutica, Inc.
- C. The Assignor and iCeutica Pty Ltd wish to: (i) confirm iCeutica, Inc.'s entitlement to assign to iCeutica Pty Ltd the Inventor's rights, title and interest in the Inventions and in the Patent Applications (as defined in the aforementioned employment contract), and (ii) to the extent necessary, assign to iCeutica Pty Ltd, any rights, title and interests the Inventor may have in the Inventions and Patent Applications that were not assigned to iCeutica Inc.

AGREED TERMS

1. Notwithstanding anything to the contrary herein, a reference in this Deed to an Assignor assigning rights, title or interest in an Invention or a Patent Application, making an acknowledgment, representation and/or confirmation with respect to an Invention or a Patent Application, refers to those Inventions and Patent Applications, each considered separately, which the Assignor invented solely or jointly with others.
2. H. William Bosch hereby acknowledges and represents that:
 - (a) the Inventions were conceived by H. William Bosch in his respective capacity as an employee of the iCeutica, Inc. and in the ordinary course of their respective ordinary duties of employment by the Assignee; and
 - (b) if and to the extent that H. William Bosch was engaged by any third party concurrently with their respective engagement by the Assignee, conception of the Inventions was entirely outside the scope of their engagement with such third party.

3. The Assignor further hereby acknowledges and confirms that all rights, title and interest in the Inventions and Patent Applications, including but not limited to:

- (a) the right to apply for registration of a Patent Application, and to own all registrations derived therefrom including reissues, extensions, confirmations, re-examinations, and inventor's certificates;
- (b) the right to sue and claim and retain damages and other remedies, including but not limited to an account of profits, for infringements of and/or wrongful interferences to a Patent Application whether or not such rights arose before the date of this Deed; and
- (c) all rights, powers, liberties and immunities conferred on the proprietor of the patents or applications relating to a Invention,

(collectively, the "**Assigned Rights**") were transferred and assigned to and vested in the Assignee absolutely at the time of filing each of the Patent Applications.

4. To the extent not already assigned to iCeutica, Inc., the Assignor hereby assigns to iCeutica Pty Ltd. his entire respective legal and beneficial right, title and interest in the Assigned Rights.

5. The Assignor agrees to execute all such further documents and do all such further acts necessary to effect the assignment of the Assigned Rights to the Assignee as contemplated by this Deed.

6. The Assignor hereby appoints the Assignee as the Assignor's attorney to do all acts and execute all documents on behalf of the Assignor to the extent necessary to vest the rights in the Assignee as contemplated by this Deed.

7. This Deed is governed by and must be construed in accordance with the laws in force in the State of Victoria. The parties submit to the exclusive jurisdiction of the courts of that State and the Commonwealth of Australia in respect of all matters arising out of or relating to this Deed, its performance or subject matter.

8. If this Deed consists of a number of signed counterparts, each is an original and all of the counterparts together constitute the same document.

9. iCeutica, Inc. hereby assigns to iCeutica Pty Ltd. their entire respective legal and beneficial right, title and interest in the Assigned Rights listed in Schedule 1 (each an Invention) which are disclosed and/or claimed in the respective corresponding patent applications also listed or described in schedule 1 (Patent Applications).

10. iCeutica, Inc. further hereby acknowledges and confirms that all rights, title and interest in the Inventions and Patent Applications, including but not limited to:

- (a) the right to apply for registration of a Patent Application, and to own all registrations derived therefrom including reissues, extensions, confirmations, re-examinations, and inventor's certificates;
- (b) the right to sue and claim and retain damages and other remedies, including but not limited to an account of profits, for infringements of and/or wrongful interferences to a Patent Application whether or not such rights arose before the date of this Deed; and
- (c) all rights, powers, liberties and immunities conferred on the proprietor of the patents or applications relating to a Invention,

(collectively, the "**Assigned Rights**") were transferred and assigned to and vested in the Assignee absolutely at the time of filing each of the Patent Applications.

Schedule 1 – Invention and corresponding Patent Applications

1. Invention: Production of encapsulated nanoparticles at high volume fractions

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000464, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901744 filed on 24 April 2009 and US Patent Application 61/172,278, also in the name of iCeutica Pty Ltd (**Provisional Applications 1**) and all patent applications that:

- (i) claim priority from Provisional Applications 1;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

2. Invention: Production of encapsulated nanoparticles at commercial scales

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000466, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901740 filed on 24 April 2009 and US Patent Application 61/172,297 also in the name of iCeutica Pty Ltd (**Provisional Applications 2**) and all patent applications that:

- (i) claim priority from Provisional Applications 2;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

3. Invention: Method for the production of commercial nanoparticle and microparticle powders

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000467, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901747 filed on 24 April 2009 and US Patent Application 61/172,300, also in the name of iCeutica Pty Ltd (**Provisional Applications 3**) and all patent applications that:

- (i) claim priority from Provisional Applications 3;

- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

4. Invention: Method for improving the dissolution profile of a biologically active material

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell, and William Bosch

Patent applications:

Patent application no. PCT/AU2010/000465, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901741 filed on 24 April 2009 and US Patent Application 61/172,301, also in the name of iCeutica Pty Ltd (**Provisional Applications 4**) and all patent applications that:

- (i) claim priority from Provisional Applications 4;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

5. Invention: A novel formulation of metaxalone

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000468, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901743 filed on 24 April 2009 and US Patent Application 61/172,281, also in the name of iCeutica Pty Ltd (**Provisional Applications 5**) and all patent applications that:

- (i) claim priority from Provisional Applications 5;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

6. Invention: A novel formulation of meloxicam

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000469, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901742 filed on 24 April 2009 and US Patent Application 61/172,284, also in the name of iCeutica Pty Ltd (**Provisional Applications 6**) and all patent applications that:

- (i) claim priority from Provisional Applications 6;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

7. Invention: A novel formulation of naproxen

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000470, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901746 filed on 24 April 2009 and US Patent Application 61/172,289, also in the name of iCeutica Pty Ltd (**Provisional Applications 7**) and all patent applications that:

- (i) claim priority from Provisional Applications 7;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

8. Invention: A novel formulation of diclofenac

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch

Patent Applications:

Patent application no. PCT/AU2010/000471, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901748 filed on 24 April 2009 and US Patent Application 61/172,291, also in the name of iCeutica Pty Ltd (**Provisional Applications 8**) and all patent applications that:

- (i) claim priority from Provisional Applications 8;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

9. Invention: A novel formulation of indomethacin

Inventors: Aaron Dodd, Felix Meiser, Marck Norett, Adrian Russell and William Bosch


Patent Applications:

Patent application no. PCT/AU2010/000472, filed on 24 April 2010 in the name of iCeutica Pty Ltd, and priority Australian Patent Application No. 2009901745 filed on 24 April 2009 and US Patent Application 61/172,295, also in the name of iCeutica Pty Ltd (**Provisional Applications 9**) and all patent applications that:

- (i) claim priority from Provisional Applications 9;
- (ii) disclose or claim the Invention or any aspect of it; or
- (iii) comprise continuations, continuations in part, divisions, re-issue or substitution of the patent applications described in paragraphs (i) and (ii) above and application for a substantially similar form of protection for the Invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process.

EXECUTED as a deed

Signed Sealed and Delivered by H. William Bosch in the presence of:)
)
)


Signature

.....
Signature of witness

.....
Name of witness
(please print)

Executed by iCeutica, Inc., a corporation of the State of Delaware:)
)
)



.....
Signature of director or company secretary*
*delete whichever does not apply

Matthew Callahan CEO

Executed by iCeutica Pty Ltd ACN 113 244)
152 in accordance with section 127(1) of the)
Corporations Act 2001 (Cth):)
)
)



.....
Signature of director or company secretary*
*delete whichever does not apply

Matthew Callahan CEO

NOTARIAL CERTIFICATE

State of Minnesota)

) ss.

County of Hennepin)

I hereby certify that attached hereto is a true and correct copy of the Assignment from H. William Bosch to iCeutica Pty Ltd, for the listed applications.

Title	Serial Number and filing date	Filing date
Production of encapsulated nanoparticles at high volume fractions	PCT/AU2010/000464	24 April 2010
	AU 2009901744	24 April 2009
	US 61/172,278	24 April 2009
Production of encapsulated nanoparticles at commercial scales	PCT/AU2010/000466	24 April 2010
	AU 2009901740	24 April 2009
	US 61/172,297	24 April 2009
Method for the production of commercial nanoparticle and microparticle powders	PCT/AU2010/000467	24 April 2010
	AU 2009901747	24 April 2009
	US 61/172,300	24 April 2009
Method for improving the dissolution profile of a biologically active material	PCT/AU2010/000465	24 April 2010
	AU 2009901741	24 April 2009
	US 61/172,301	24 April 2009
A novel formulation of metaxalone	PCT/AU2010/000468	24 April 2010
	AU 2009901743	24 April 2009
	US 61/172,281	24 April 2009
A novel formulation of meloxicam	PCT/AU2010/000469	24 April 2010
	AU 2009901742	24 April 2009
	US 61/172,284	24 April 2009
A novel formulation of naproxen	PCT/AU2010/000470	24 April 2010
	AU 2009901746	24 April 2009
	US 61/172,289	24 April 2009
A novel formulation of diclofenac	PCT/AU2010/000471	24 April 2010
	AU 2009901748	24 April 2009
	US 61/172,291	24 April 2009
A novel formulation of indomethacin	PCT/AU2010/000472	24 April 2010
	AU 2009901745	24 April 2009
	US 61/172,295	24 April 2009

Denise Wynn
Notary Public

(SEAL)

Dated: December 16, 2011

